Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

RainBIO Inc
Profile last edited on: 3/14/2023      CAGE: 8PEN1      UEI: FAKRSACAQRQ7

Business Identifier: Ocular gene therapy pioneer focused on blindness in the cornea
Year Founded
2020
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

8628 Valley Brook Drive
Raleigh, NC 27613
   (919) 962-7633
   info@rainbio.us
   www.rainbio.us
Location: Single
Congr. District: 02
County: Wake

Public Profile

RainBIO is the only ocular gene therapy pioneer focused on blindness in the cornea. Company's adeno-associated virus (AAV) vector gene therapy can directly correct cornea cellular function to maintain or restore vision in patients at risk of blindness from a number of diseases. RainBIO's groundbreaking first-in-class lead program for corneal clouding in Mucopolysaccharidosis type 1 (MPS1) patients who have vision loss from this rare genetic disease opens up a new field in ocular gene therapy.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$367,624
Phase II Dollars
$0
Total Awarded
$367,624

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $367,624
Project Title: Tolerability and Potency of Sequential and Repeated AAV Corneal Gene Therapy

Key People / Management

  Fran Martin -- President

  Ben Yerxa -- Chairman and CEO

  Chris Brasfield

  Brian Gilger -- Founder

  Matthew Hirsch -- Founder

Company News

There are no news available.